NewswireToday - /newswire/ -
Holmes Chapel, Cheshire, United Kingdom, 2012/02/20 - Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, announces the appointment of Dr Martin Page as scientific consult - PRECOS.co.uk.
Dr Page brings over 28 years’ experience of oncology R&D leadership gained from the pharmaceutical and biotechnology sectors across UK, Europe and USA. His extensive therapeutic experience and industry knowledge will contribute to the company’s expert delivery of innovative patient relevant models for oncology research.
Dr Page has led multiple teams discovering novel targeted small molecule and MAb anti-cancer agents which have entered clinical trials. Prior to this new role, he was Vice President, Head of Global Oncology Research for Johnson & Johnson Pharmaceuticals, responsible for laboratories in Belgium and USA.
Dr Neil Rotherham, chairman of the PRECOS board comments,“We are delighted to welcome Martin to our team of visionary scientists. Dr Page’s expertise will be invaluable in PRECOS’ continued success as a trusted and preferred partner for some of the world’s leading oncology research companies.”
Previously Dr Page has held senior positions as Oncology Therapeutic Area Head/Europe for Glaxo-Wellcome and Senior Director positions in the biotechnology companies Oxford GlycoSciences and Oncogene Sciences Inc. He will support PRECOS to continue to advance its world-leading work in the evaluation of potential therapeutic agents, regimens and basic research into deriving the most relevant in vitro and in vivo screening models
“I am extremely excited to work alongside the PRECOS team of expert scientists who are leading the way in providing robust models to enable testing of the next generation of oncology drug candidates,” said Dr Page. “PRECOS translates its expertise in cancer drug development to enable the development of medicines with real patient benefits and my appointment reinforces the ambition and potential of PRECOS to contribute in a significant way to the growing cancer therapy market.”
Dr Martin Page will be attending the AACR conference, Chicago, March 31st - April 4th 2012, booth #4306, where PRECOS will be showcasing several new platforms for pre-clinical oncology research. To arrange a meeting please contact PRECOS on +44 (0)870 166 6234, email enquiries[.]precos.co.uk or visit precos.co.uk for further information.
About PRECOS Ltd
PRECOS Ltd (precos.co.uk) is a flexible pre-clinical research and development service with a specific focus on oncology, with an established track record in providing expert support to direct cancer drug development projects from concept to clinic. PRECOS evaluates the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients. The PRECOS team of expert scientists assist in the selection and execution of appropriate analytical systems by a staged approach of in vitro studies, in vivo model development, subsequent in vivo mechanistic and therapeutic evaluations and post-study analyses, all conveyed with added value through specialist scientific interpretation of the data. PRECOS scientists apply cutting-edge technology and ideas to individual research programmes and delivers a flexible, tailored approach to all research objectives, whether a one-off service or a complete research programme.
PRECOS, an acronym of Pre-Clinical Oncology Services, was officially launched as a specialist business unit of the University of Nottingham (UK) in 2004. PRECOS evolved from the research expertise of the Division of Pre-clinical Oncology (formerly Academic Unit of Cancer Studies), which had successful collaborations with pharmaceutical and biotech companies in the UK, EU, US and Japan for over a decade.